Preliminary study results indicate that the median survival rate for the patients who received Metastron was 27.7 months. Patients randomized to receive chemotherapy alone had a median survival of 16.8 months.
Prostate cancer is the most common form of cancer in men.
When a cancer spreads from its point of origin to other parts of the body, the process is known as metastasis. Certain types of cancers, such as prostate and breast cancers, tend to spread to the bone, causing a painful disorder called metastatic bone disease. Caution should also be used in patients with platelet counts below 60,000 or white blood cell counts below 2400. Some patients have reported a transient increase in bone pain at 36 to 72 hours following injection. This can usually be controlled with analgesics.